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Abstract: PURPOSE Testicular granulosa cell tumors (tGrCT) are rare sex cord-stromal tumors. This
review aims to synthesize the available evidence regarding the clinical presentation and clinicopatholog-
ical characteristics, treatment and outcomes. METHODS We conducted a systematic literature search
using the most important research databases. Whenever feasible, we extracted the data on individual
patient level. RESULTS From 7863 identified records, we included 88 publications describing 239 pa-
tients with tGrCT. The majority of the cases were diagnosed with juvenile tGrCT (166/239, 69%), while
73/239 (31%) patients were diagnosed with adult tGrCT. Mean age at diagnosis was 1.5 years (± 5 SD)
for juvenile tGrCT, and 42 years (± 19 SD) for adult tGrCT. Information on primary treatment was
available in 231/239 (97%), of which 202/231 (87%) were treated with a radical orchiectomy and 20/231
(9%) received testis sparing surgery (TSS). Local recurrence after TSS was observed in 1/20 (5%) cases.
Metastatic disease was never observed in men with juvenile tGrCT but in 7/73 (10%) men with adult
tGrCT. In 5/7 men with metastatic tGrCT, metastases were diagnosed at initial staging, while 2/7 pa-
tients developed metastases after 72 and 121 months of follow-up, respectively. Primary site of metastasis
is represented by the retroperitoneal lymph nodes, but other sites including lungs, liver, bone and inguinal
lymph nodes can also be affected. In comparison with non-metastatic adult tGrCT, men with metastatic
adult tGrCT had significantly larger primary tumors (70 vs 24 mm, p 0.001), and were more likely to
present with angiolymphatic invasion (57% vs 4%, p 0.002) or gynecomastia (29% vs 3%, p 0.019). In five
out of seven men with metastatic disease, resection of metastases or platinum-based chemotherapy led
to complete remission. CONCLUSION Juvenile tGrCT represent a benign entity whereas adult tGCTs
have metastatic potential. Tumor size, presence of angiolymphatic invasion or gynecomastia represent
risk factors for metastatic disease. The published literature supports the use of testis sparing surgery
but there is only limited experience with adjuvant therapies. In the metastatic setting, the reviewed
literature suggests that aggressive surgical and systemic treatment might cure patients.
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Abstract
Purpose Testicular granulosa cell tumors (tGrCT) are rare sex cord-stromal tumors. This review aims to synthesize the 
available evidence regarding the clinical presentation and clinicopathological characteristics, treatment and outcomes.
Methods We conducted a systematic literature search using the most important research databases. Whenever feasible, we 
extracted the data on individual patient level.
Results From 7863 identified records, we included 88 publications describing 239 patients with tGrCT. The majority of the 
cases were diagnosed with juvenile tGrCT (166/239, 69%), while 73/239 (31%) patients were diagnosed with adult tGrCT. 
Mean age at diagnosis was 1.5 years (± 5 SD) for juvenile tGrCT, and 42 years (± 19 SD) for adult tGrCT. Information on 
primary treatment was available in 231/239 (97%), of which 202/231 (87%) were treated with a radical orchiectomy and 
20/231 (9%) received testis sparing surgery (TSS). Local recurrence after TSS was observed in 1/20 (5%) cases. Metastatic 
disease was never observed in men with juvenile tGrCT but in 7/73 (10%) men with adult tGrCT. In 5/7 men with metastatic 
tGrCT, metastases were diagnosed at initial staging, while 2/7 patients developed metastases after 72 and 121 months of 
follow-up, respectively. Primary site of metastasis is represented by the retroperitoneal lymph nodes, but other sites includ-
ing lungs, liver, bone and inguinal lymph nodes can also be affected. In comparison with non-metastatic adult tGrCT, men 
with metastatic adult tGrCT had significantly larger primary tumors (70 vs 24 mm, p 0.001), and were more likely to present 
with angiolymphatic invasion (57% vs 4%, p 0.002) or gynecomastia (29% vs 3%, p 0.019). In five out of seven men with 
metastatic disease, resection of metastases or platinum-based chemotherapy led to complete remission.
Conclusion Juvenile tGrCT represent a benign entity whereas adult tGCTs have metastatic potential. Tumor size, presence 
of angiolymphatic invasion or gynecomastia represent risk factors for metastatic disease. The published literature supports 
the use of testis sparing surgery but there is only limited experience with adjuvant therapies. In the metastatic setting, the 
reviewed literature suggests that aggressive surgical and systemic treatment might cure patients.
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NOS  Not otherwise specified
PRISMA  Preferred reporting items for systematic 
reviews and meta-analysis
IQR  Interquartile range
SD  Standard deviation
ROC  Receiver operating curve
AFP  Alpha fetoprotein
HCG  Human chorionic gonadotropin
LDH  Lactate dehydrogenase
RPLND  Retroperitoneal lymph node dissection
BEP  Bleomycin, etoposide and cisplatin
RPLN  Retroperitoneal lymph nodes
HPF  High-power field
DC  Doxorubicin–cisplatin
OATH  OrphAn Testis Histologies
Introduction
Testicular granulosa cell tumors (tGrCT) are a rare group 
of sex cord-stromal tumors (SCST) originating from epithe-
lial elements of the sex cord. While they represent the most 
common SCST in the ovary (Young 2005), the testicular 
manifestation was only reported sporadically since the first 
description in 1952 (Laskowski 1952). According to the 
current World Health Organization (WHO) classification of 
Tumors of the Urinary System and Male Genital Organs, two 
histologic subtypes are distinguished: The juvenile tGrCT 
and the less frequent adult tGrCT (Idrees et al. 2017). While 
the juvenile subtype accounts for 6% of all prepubertal tes-
ticular tumors and represents the most frequent congenital 
testicular tumor (Kao et al. 2015), the adult tGrCT is rare 
and only reported in small case series and case reports. For 
both histological subtypes, the risk of metastatic spread is ill 
defined (Cecchetto et al. 2010; Mostofi et al. 1959).
Due to the rarity of tGrCT, there are several unanswered 
questions regarding the optimal management of patients 
with localized or metastatic tGrCT. The aim of this system-
atic literature review was to provide an overview of the avail-
able data on tGrCT patients, regarding clinical presentation, 
clinicopathologic factors predicting metastatic disease, expe-
rience with testis sparing surgery, sites of metastasis, and 
outcome and treatment success in case of metastatic disease.
Methods
Evidence acquisition
Data acquisition and search strategy
This systematic literature review was conducted based on 
the Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) statement (Moher et al. 2009, 
2015). Prior to data acquisition, the review protocol and 
search strategy were published on the University of York’s 
PROSPERO registry (http://www.crd.york.ac.uk/PROSP 
ERO; registration number CRD42018110112).
Our literature search identified articles published up to 
5th May 2018 and covered the most significant electronic 
databases (MEDLINE, EMBASE, Scopus, Cochrane Data-
base of Systematic Reviews and Web of Science). A clini-
cal medical librarian applied a broad approach using sev-
eral combinations, synonyms and search terms related to 
“granulosa cell tumor”, “sex cord tumor”, “stromal tumor” 
or “interstitial cell tumor” to identify all relevant articles. 
Non-English literature was excluded unless the abstract was 
available in English or the full text in French, Spanish, Ital-
ian or German. The reference lists of the identified publica-
tions were screened manually to identify additional studies. 
A detailed description of our search strategy is shown in 
Appendix 1.
Deduplication of the resulting list of publications was 
achieved automatically using the close match function of our 
reference management software. The remaining duplicate 
articles were identified via manual deduplication done by 
two authors (JG, KS). The same authors screened the titles 
and abstracts independently to select publications that ful-
filled the eligibility criteria and came to a consensus about 
the inclusion of those studies. Data of the same study that 
appeared in multiple publications were counted only once 
in the synthesis. Disagreements were discussed and resolved 
by consensus or by third-party arbitration (CDF). Any case 
reports, clinical case series and other reports describing 
patients with juvenile or adult tGrCT were included.
Types of outcome measures included
Studies reporting clinical or pathological variables, treat-
ment of local or metastatic disease, site of metastases, dis-
ease-free, cancer-specific or overall survival were eligible 
for this review. To capture all relevant literature, our search 
strategy did not include predefined interventions, controls 
or outcomes.
Data extraction
Based on the Cochrane Consumers and Communication 
Review Group’s data extraction template, a data extraction 
sheet was developed and improved after a pilot-testing phase 
on twenty randomly selected eligible studies. Data on study 
design, patient characteristics, clinicopathological risk fac-
tors, treatment and follow-up were collected. Whenever fea-
sible, data were gathered on single patient level.
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Statistical analysis
Receiver operating curve (ROC) analyses using the maximal 
Youden’s index (= Sensitivity + Specificity − 1) (Youden 
1950) were used to determine an optimal cut-off value of 
continuous variables. 2 × 2 table analysis was performed 
with R version 3.3.1 (R Foundation for Statistical Comput-
ing, Vienna, Austria) using the package epiR. Descriptive 
data are presented as median and interquartile range (IQR). 
Weighted medians were used to estimate already statistically 
processed data of cohort studies as well as individual patient 
data of single case reports. The results for continuous nor-
mally distributed variables are expressed as mean ± stand-
ard deviation (SD). Continuous non-normally distributed 
variables are presented as median and interquartile ranges 
(IQR) and categorical variables are presented as percent-
age. Categorical data were compared using the Chi-square 
test of independence. Normally distributed continuous vari-
ables were analyzed using the independent samples t test, 
while the Mann–Whitney U test was used for non-normally 
distributed continuous variables. All p values < 0.05 were 




After automated and manual deduplication, 98 of 3542 pub-
lications which met the initial search criteria were eligible 
for full-text review after screening of title and abstract. We 
finally included 88 studies, resulting in a dataset of 239 
patients (Fig. 1). Data regarding follow-up were available 
in 185 of 239 (77%) patients. Mean follow-up time was 
48 months (± 40 SD).
Fig. 1  Flowchart of the study selection process
2832 Journal of Cancer Research and Clinical Oncology (2020) 146:2829–2841
1 3
Subgroups, demographics, clinical symptoms 
and laboratory findings
We identified 239 cases of tGrCT, of which 166 (69%) 
presented with the histological variant juvenile tGrCT and 
73 (31%) with adult tGrCT (Table 1). Juvenile tGrCT were 
diagnosed at a mean age of 1.5 years (± 5 SD), with single 
reports of diagnosis in early adulthood (27 and 34 years) 
(Gravas et al. 2007; Lin et al. 2008). Patients with adult 
tGrCT were diagnosed at a mean age of 42 years (± 19 
SD). Overall, data about clinical presentation were 
available in 171 of the 239 patients (72%). The majority 
of patients presented with a testicular mass (78/171, 46%) 
or testicular enlargement (71/171, 42%), whereas scro-
tal pain was only described in 8/171 (5%) cases. Alpha-
fetoprotein (AFP) was elevated in 18/171 (11%) of the 
cases, whereas other tumor markers like human chorionic 
gonadotropin (HCG) and lactate dehydrogenase (LDH) 
were elevated in only 3/171 (2%) and 2/171 (1%) patients, 
respectively. Hormonal changes were reported in 19/171 
(11%), including gynecomastia (7/171, 4%) and anomaly 
of puberty (2/171, 1%). History of ipsi- or contralateral 
Table 1  Patient characteristics
AFP alpha-fetoprotein, bHCG beta-human chorionic gonadotropin, IQR interquartile range, LDH lactate dehydrogenase, SD standard deviation, 
IQR inter quartile range, *this column includes only patients of which individual patient level data were available
Individual patient level of 81 reports* Study-level data from 88 reports






All testicular granulosa cell tumors
Number of patients 138 65 73 239
Age (years)
 Mean (± SD) 23 (± 25) 1.5 (± 5) 42.0 (± 19) 23 (± 25)
  Available 137 (99) 65 (100) 72 (99)
  Missing 1 (1) 0 (0) 1 (1)
Size (mm)
 Median (IQR) 23 (14–44) 20 (13–38) 26 (15–45) 21 (15–44)
  Available 100 (72) 36 (55) 64 (88)
  Missing 38 (28) 29 (45) 9 (12)
Side
 Available 133 (96) 61 (94) 72 (99)
 Missing 5 (4) 4 (6) 1 (1)
  Left 62 (46) 24 (39) 38 (53) 101 (42)
  Right 66 (50) 33 (54) 33 (46) 92 (38)
  Bilateral 5 (4) 4 (7) 1 (1) 5 (2)
Clinical presentation
 Available 104 (75) 63 (97) 41 (56) 171 (72)
 Missing 34 (25) 2 (3) 32 (44) 68 (28)
  Testicular enlargement 45 (43) 24 (38) 21 (51) 71 (42)
  Testicular mass 37 (36) 22 (35) 15 (37) 78 (46)
  Hormonal changes 13 (13) 9 (14) 4 (10) 19 (11)
  Abdominal mass 7 (7) 7 (11) – 9 (5)
  Gynecomastia 6 (6) 2 (3) 4 (10) 7 (4)
  Incidental finding 9 (9) 6 (10) 3 (7) 9 (5)
  Scrotal pain 8 (8) 2 (3) 6 (15) 8 (5)
  Anomaly of puberty 2 (2) 2 (3) – 2 (1)
  AFP elevation 12 (12) 11 (17) 1 (2) 18 (11)
  bHCG 3 (3) 2 (3) 1 (2) 3 (2)
  LDH 2 (2) 1 (2) 1 (2) 2 (1)
 Cryptorchidism ipsilateral 10 (10) 9 (14) 1 (2) 16 (9)
 Cryptorchidism contralateral 5 (5) 3 (5) 2 (5) 5 (3)
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Table 2  Treatment and outcome of patients with juvenile and adult tGrCT
Author Year No. of cases Primary treat-








disease (no. of 
patients)
Histology Mean follow-up 
time in months
Outcome during 
follow-up (no. of 
patients)
Summary statistics
 All tGrCT 239 140 orchiec-
tomy, 62 
gonadectomy, 
20 TSS, 7 
laparotomy, 2 
biopsy only
5 RPLN, 1 ILN, 
1 lung, 1 liver, 
1 bone
3 RPLND, 4 
Chemo, 1 
ILND
1 RT, 1 metasta-
sectomy





166 72 orchiectomy, 
62 gonadec-
tomy, 15 TSS, 
7 laparotomy, 
2 biopsy only





73 68 orchiectomy, 
5 TSS
5 RPLN, 1 ILN, 
1 lung, 1 liver, 
1 bone
3 RPLND, 4 
Chemo, 1 
ILND
1 RT, 1 metasta-
sectomy




 Trenti, E., et al. 2018 1 TSS aGCT 12 NED
 Tartar, T., et al. 2017 1 Orchiectomy jGCT 
 Elbachiri, M., 
et al.




2017 1 Orchiectomy jGCT 7 NED
 Mohapatra, A., 
et al.
2016 1 Orchiectomy RPLN RPLND aGCT 32 NED
 Liu, S. and P. 
Koscheski
2016 1 TSS jGCT 
 Karachaliou, 
F., et al.
2016 1 jGCT 18 NED
 Bani, M. A., 
et al.
2016 1 Orchiectomy aGCT 4 NED
 Al-Alao, O., 
et al.
2016 1 Orchiectomy aGCT 12 NED
 Vallonthaiel, 
A. G., et al.
2015 1 Orchiectomy aGCT LTFU
 Kao, Chia-Sui 2015 70 62 gonadec-
tomy, 6 TSS, 2 
biopsy only
jGCT 61 24 NED
 González, B. 
I., et al.
2015 1 Orchiectomy jGCT 
 Giulianelli, R., 
et al.
2015 1 Orchiectomy aGCT 12 NED
 Bani, M. A., 
et al.
2015 1 Orchiectomy aGCT LTFU
 Tsitouridis, I., 
et al.
2014 1 Orchiectomy aGCT 12 NED
 Tanner, S. B., 
et al.
2014 1 Orchiectomy aGCT NED
 Schubert, T. E. 
O., et al.
2014 1 Orchiectomy aGCT LTFU
 Illescas, T., 
et al.
2014 1 Orchiectomy jGCT LTFU
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Table 2  (continued)
Author Year No. of cases Primary treat-








disease (no. of 
patients)
Histology Mean follow-up 
time in months
Outcome during 




2014 1 Orchiectomy jGCT LTFU
 Cornejo, K. 
M. and R. H. 
Young
2014 32 30 orchiectomy, 
2 TSS
aGCT 37 17 NED, 1 orchi-
ectomy
 Claros, O. R., 
et al.
2014 1 Orchiectomy jGCT 48 NED
 Aranha, A., 
et al.
2014 1 Orchiectomy jGCT 24 NED
 Norman, R. 
W., et al.
2013 1 Orchiectomy aGCT 18 NED
 Miliaras, D., 
et al.
2013 1 Orchiectomy aGCT 24 NED
 Partalis, N., 
et al.
2012 1 jGCT 12 NED
 Muhlschlegel, 
J. M., et al.
2012 1 TSS jGCT 24 NED
 Couture, J. and 
S. Bolduc
2012 1 Orchiectomy jGCT 
 Bulotta, A. L., 
et al.
2012 1 Orchiectomy jGCT 1 NED
 Yu, D. C., et al. 2011 1 Orchiectomy jGCT 17 NED
 Tiscione, D., 
et al.
2011 1 TSS aGCT LTFU
 Song, Z., et al. 2011 1 Orchiectomy aGCT LTFU
 Zugor, V., et al. 2010 2 2 orchiectomy jGCT 17 2 NED
 Seixas-Mike-
lus, S. A., 
et al.
2010 1 Orchiectomy jGCT 12 NED
 Oscar Tapia, 
E., et al.
2010 1 Orchiectomy jGCT 8 NED





2010 5 3 TSS jGCT 
 Peterson, C. 
and S. Skoog
2008 1 Orchiectomy jGCT LTFU
 Mitra, A., et al. 2008 1 Orchiectomy aGCT LTFU
 Lin, K.-H., 
et al.
2008 1 Orchiectomy jGCT 96 NED
 Kucukodaci, 
Z., et al.
2008 1 Orchiectomy aGCT 10 NED
 Kim, D. J., 
et al.
2008 1 Orchiectomy aGCT 12 NED
Hammerich, K. 
H., et al.
2008 1 Orchiectomy Lung Chemo (BEP) aGCT 13 NED
 Gupta, A., 
et al.
2008 1 Orchiectomy aGCT 12 NED
 Dudani, R., 
et al.
2008 1 Orchiectomy jGCT 6 NED
 Yikilmaz, A. 
and E. Y. Lee
2007 1 jGCT 
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Table 2  (continued)
Author Year No. of cases Primary treat-








disease (no. of 
patients)
Histology Mean follow-up 
time in months
Outcome during 
follow-up (no. of 
patients)
 Trobs, R. B., 
et al.
2007 1 Orchiectomy jGCT 47 NED
 Lopez, J. I. 2007 1 Orchiectomy aGCT 12 NED
 Gravas, S., 
et al.





2007 1 Orchiectomy aGCT LTFU
 Barroca, H., 
et al.
2007 1 Orchiectomy jGCT 
 Alexiev, B. A., 
et al.
2007 1 Orchiectomy jGCT 
 Zugor, V., et al. 2006 1 Orchiectomy jGCT 12 NED
 Hisano, M., 
et al.
2006 1 Orchiectomy aGCT 48 NED
 Arzola, J., 
et al.
2006 1 Orchiectomy aGCT 9 NED
 Suppiah, A., 
et al.
2005 1 Orchiectomy Bone Metastasectomy aGCT 4 NED
 Shukla, A. R., 
et al.
2004 3 2 orchiectomy, 
1 TSS
jGCT 78 3 NED
 Guzzo, T., 
et al.
2004 1 Orchiectomy aGCT LTFU
 Moore, W., 
et al.
2003 1 Orchiectomy jGCT 
 Fidda, N. and 
D. A. Weeks
2003 1 Orchiectomy jGCT 18 NED
 Fagin, R., et al. 2003 1 Orchiectomy jGCT 6 NED
 Bryan, D. E., 
et al.
2003 3 3 orchiectomy jGCT 8 2 NED
 Wang, B. Y., 
et al.
2002 1 TSS aGCT LTFU
 Nieto, N., et al. 2002 1 Orchiectomy jGCT 30 NED
 Antunes, L., 
et al.
2002 1 Orchiectomy jGCT 
 Ji, E. K. and K. 
S. Cho
2001 1 Orchiectomy aGCT LTFU
 Al-Bozom, I. 
A., et al.
2000 1 Orchiectomy aGCT 7 NED
 Harms, D. and 
L. R. Kock
1997 11 8 orchiectomy, 
1 TSS
jGCT 8 NED, 3 LTFU
 Chan, Y. F., 
et al.
1997 2 2 orchiectomy jGCT 9 2 NED
 Perez-Atayde, 
A. R., et al.
1996 6 6 orchiectomy jGCT 6 NED, 1 died
 Goswitz, J. J., 
et al.




1995 1 Orchiectomy jGCT 
 Tanaka, Y., 
et al.
1994 1 Laparotomy jGCT 72 NED
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cryptorchidism was reported in 18/166 (11%) of juvenile 
tGrCT and in 3/73 (4%) of adult tGrCT.
Local treatment and pathological findings
In 231 of 239 cases, information about treatment was 
available (Table 2). Most patients underwent orchiectomy 
(202/231, 87%), while testis sparing surgery (TSS) was per-
formed in 20 cases (9%). Local recurrence 3 months after 
TSS was reported in one patient (1/20, 5%). After receiving 
a salvage hemiscrotectomy, the patient remained disease free 
for at least 18 months (Gravas et al. 2007). Seven patients 
(3%) with intra-abdominal cryptorchidism underwent lapa-
rotomy. Two patients (1%) underwent testicular biopsy 
only without any further treatment. The median tumor size 
of tGCTs was 21 mm (IQR 15–44). The most frequently 
described pathological findings included high mitotic rate 
(53/239, 22%), necrosis (12/239, 5%), angiolymphatic inva-
sion (10/239, 4%) and pleomorphism (10/239, 4%). Other 
features like infiltrating margins, extracapsular invasion or 
calcification were seen in four patients or less. The most fre-
quently reported immunohistochemistry included vimentin 
(58/239, 24%), inhibin (55/239, 23%) and calretinin (24/239, 
10%).
Metastatic disease
While all of the 166 reported cases of juvenile tGrCT were 
exclusively benign, 7 out of 73 (10%) patients with adult 
tGrCT showed metastatic disease (Table 3). Mean age at 
diagnosis of patients with metastatic tGrCT was 45 years 
(± 14 SD). The median primary tumor size of metastatic 
cases was 70 mm (IQR: 51–90). Painless testicular enlarge-
ment (n = 3) or palpable mass (n = 2) was the most frequent 
Table 2  (continued)
Author Year No. of cases Primary treat-








disease (no. of 
patients)
Histology Mean follow-up 
time in months
Outcome during 





1993 7 7 orchiectomy P1: RPLN, liver 
P2: RPLN, 
ILN









1992 1 Orchiectomy aGCT 24 NED
 May, D., et al. 1992 1 Laparotomy jGCT 6 NED
 Matoska, J., 
et al.
1992 1 Orchiectomy RPLN RPLND, RT aGCT 168 NED
 Yokoyama, J., 
et al.
1990 1 Orchiectomy jGCT 24 NED
 Due, W., et al. 1990 1 Orchiectomy aGCT 2.25 Died
 Chan, J. K., 
et al.
1990 1 Laparotomy jGCT 30 NED
 Gaylis, F. D., 
et al.
1989 1 Orchiectomy aGCT LTFU
 Nistal, M., 
et al.
1988 1 Orchiectomy jGCT 24 NED
 Uehling, D. T., 
et al.
1987 1 Orchiectomy jGCT 36 NED
 Raju, U., et al. 1986 1 Laparotomy jGCT 60 NED
 Young, R. H., 
et al.
1985 3 3 laparotomy jGCT 6 NED
 Talerman, A. 1985 1 Orchiectomy aGCT 36 NED
 Pinto, M. M. 1985 1 Orchiectomy jGCT 
 Lawrence, W. 
D., et al.
1985 14 14 orchiectomy jGCT 4 NED
 Crump, W. D. 1983 1 jGCT 0 Died after birth
aGCP adult granulosa cell tumor, jGCP juvenile granulosa cell tumor, MFS metastatic-free survival, RPLND retroperitoneal lymph node dissec-
tion, ILN inguinal lymph nodes, ILND inguinal lymph node dissection, RT radiotherapy, DOD died of disease, NED no evidence of disease, SD 
stable disease, Chemo: BEP bleomycin, etoposide, cisplatin, DC doxorubicin–cisplatin, E etoposide
2837Journal of Cancer Research and Clinical Oncology (2020) 146:2829–2841 
1 3
clinical presentation in metastatic tGCTs, two patients also 
presented with gynecomastia. One patient was diagnosed 
incidentally during an ultrasound examination. None of the 
reported metastatic cases showed elevated AFP, HCG or 
LDH.
Risk factors for metastatic disease
Predictive variables for metastatic disease included tumor 
size, angiolymphatic invasion and presence of gynecomastia 
(supplementary Table 1). According to ROC analyses, the 
ideal cut-off for tumor size to predict metastatic disease was 
46 mm (AUC 0.86 95% CI 0.76–0.93). A tumor size above 
46 mm was observed in 7/7 (100%) metastatic and in (10/61, 
16%, p value: < 0.001) non-metastatic patients. Angiolym-
phatic invasion was more common in metastatic compared to 
non-metastatic disease (4/7 (57%) vs. 8/54 (15%), p = 0.002). 
Furthermore, gynecomastia was more common in metastatic 
compared to non-metastatic disease (29% vs. 3%, p = 0.019).
Table 3  Clinical and 
pathological features of 
metastatic and non-metastatic 
adult granulosa cell tumors
Normally distributed continuous variables were analyzed using the independent samples t test. The Mann–
Whitney U test was used for non-normally distributed continuous variables. The Chi-square test was used 
for categorical variables
SD standard deviation, tGrCT testicular granulosa cell tumor, IQR inter quartile range, AFP alpha fetopro-
tein, HCG human chorionic gonadotropin, LDH lactate dehydrogenase
Metastatic adult tGrCT, n = 7 (%) Non-metastatic adult 
tGrCT, n = 66 (%)
P value
Age (years) Available 7/7 Available 66/66
 Mean (± SD) 45 (± 14) 42 (± 19) 0.659
  < 50 years 3 (43) 35 (53)
  ≥ 50 years 4 (57) 31 (47) 0.223
Tumor size (mm) Available 6/7 Available 59/66
 Median (IQR) 70 (51–90) 24 (14–42) 0.001
  < 46 mm 0 (0) 49 (83)
  ≥ 46 mm 6 (100) 10 (17) < 0.001
Tumor markers Available 7/7 Available 35/66
 APF 0 (0) 1 (2)
 HCG 0 (0) 1 (2)
 LDH 0 (0) 1 (2)
Clinical presentation Available 7/7 Available 35/66
 Median time to diagnosis 7 months 24 months 0.364
 Testicular enlargement 3 (43) 18 (27) 0.754
 Palpable mass 2 (29) 13 (20) 0.960
 Gynecomastia 2 (29) 2 (3) 0.019
 Incidental finding 1 (14) 2 (3) 0.453
 Hormonal changes 1 (14) (T↓, FSH/LH↑) 2 (3) 0.102
 Infertility 0 (0) 0 (0) –
 Scrotal pain 0 (0) 6 (9) 0.316
Pathology features Available: 7/7 Available: 47/66
 Angiolymphatic invasion 4 (57) 2 (4) 0.002
 Necrosis 2 (29) 4 (9) 0.115
 Pleomorphism 2 (29) 5 (11) 0.103
 High mitotic index 2 (29) 8 (17) 0.109
 Extracapsular growth 2 (29) 2 (4) 0.771
 Infiltrating margins 1 (14) 0 (0) 0.299
 Atypias 0 (0) 1 (2) 0.3
Staining
 Inhibin 4 (57) 13 (28) 0.641
 Vimentin 3 (43) 23 (49) 0.148
 Calretinin 0 (0) 8 (17) –
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Onset of metastatic disease
In five patients, metastatic disease was diagnosed at initial 
staging. The primary site of metastatic disease at staging 
included retroperitoneal lymph nodes (RPLN) in four and 
the chest in one patient (Fig. 2). Overall, three patients 
developed metastatic disease recurrence: Two patients 
with localized disease at staging showed metastatic recur-
rence (2/66, 3%) after a 72 and 121 months, respectively. 
Sites of recurrence included distal tibia in one case and the 
retroperitoneum and liver in the second case. One patient 
with metastatic disease in the retroperitoneum at initial 
staging showed recurrence in the inguinal lymph nodes 
later on (Table 4).
Treatment of metastatic disease
The median follow-up time for men with metastatic disease 
was 14 months (IQR: 9–83). Of seven patients with metasta-
sized tGrCT, five patients showed complete remission after 
treatment (Table 4). Patient #1 had a metastatic recurrence 
in the distal left tibia 6 years after diagnosis and received a 
below knee amputation and was free of disease for at least 
another 4 months (Suppiah et al. 2005). Patient #2 and #3 
showed metastatic disease in the RPLN at initial staging 
were treated with RPLND and remained without evidence 
of disease during a total follow-up time of 32 (Mohapatra 
et al. 2016) and 168 months (Matoska et al. 1992), respec-
tively. Patient #4 with metastatic disease in the RPLN 
received four cycles of BEP and remained disease free for 
at least 6 months (Elbachiri et al. 2017). Patient #5 pre-
sented with lung metastases at initial staging, received 6 
cycles of BEP and showed no evidence of disease for at 
least 13 months (Hammerich et al. 2008). Patient #6 was 
diagnosed with RPLN and liver metastases 121 months after 
orchiectomy. He subsequently received chemotherapy with 
doxorubicin–cisplatin (DC) but died of progressive disease 
134 months after initial diagnosis (Matoska et al. 1992). 
Patient #7 underwent a modified retroperitoneal lymph node 
dissection, which revealed metastatic involvement of four 
Fig. 2  Anatomical locations of metastatic sites both at initial staging during follow-up
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lymph nodes. Consequently, the patient was treated with one 
cycle of chemotherapy with etoposide, which was discon-
tinued because of side effects. After 2 months, ipsilateral 
inguinal lymph node metastases were detected. After resec-
tion and additive radiotherapy, he remained disease free for 
at least 14 months (Matoska et al. 1992).
Discussion
Our systematic review of published case series represents 
the most comprehensive summary of the available literature 
regarding tGCTs providing recommendation for (1) local 
therapy, (2) risk factors for metastatic disease and recom-
mendations for follow-up and (3) treatment of metastatic 
disease.
First, based on the low local recurrence rate of 5%, the 
use of TSS as primary treatment can be considered in case 
of juvenile tGrCT and in selected cases with small adult 
tGrCTs. However, the evidence is limited and only based 
on a minority of the cases treated with TSS. Patients should 
be informed about the low risk of local recurrence and the 
requirement for a completion orchiectomy in case of angio-
lymphatic invasion. If TSS is to be used, follow-up with 
testicular ultrasound should be considered.
Second, to identify adult tGrCT with metastatic potential, 
a larger tumor size, presence of angiolymphatic invasion 
and presence of gynecomastia represent predictive variables 
with good discriminatory accuracy. Given the high nega-
tive predictive value of those risk and late onset of recur-
rences, no general recommendation for regular follow-up 
with cross-sectional imaging of the abdomen and chest can 
be given. Instead, we recommend regular follow-up exami-
nation by a uro-oncologist for patients with risk factors on 
an annual basis for an extended postoperative period of up 
to 10–15 years.
On the other hand, given the low risk of recurrence of 
3%, we recommend patients without risk factors or juvenile 
tGrCT to be followed up by their general practitioner. Imag-
ing and/or referral to a uro-oncologist is recommended in 
case of clinical suspicion. Our data do not support the use 
of germ-cell tumor markers such as AFP, HCG, LDH during 
the follow-up of tGrCT patients.
Third, the non-existence of data regarding adjuvant ther-
apy for localized disease questions the use of any adjuvant 
therapies. The fact that in 80% the primary metastatic tGrCT 
landing site was the retroperitoneum adjuvant RPLND might 
have the potential to cure some patients with micro-meta-
static disease. However, as our data do not provide evidence 
that tGrCT have a discreet step-wise progression involving 
a specific primary landing site, adjuvant RPLND is not 
recommended.
Fourth, although the experience in men with metastatic 
disease is limited, response to surgical resection of metasta-
ses and/or chemotherapy with BEP was observed. We, there-
fore, suggest an aggressive curative approach with surgery 
alone or in combination with cisplatin-based chemotherapy 
in case of incomplete resection.
Limitations
The published literature only consists of retrospective case 
reports and small case series. Moreover, reports of clinico-
pathological features were often inconsistent, making this 
analysis prone to bias. Our search strategy was designed 
and reviewed both by clinicians as well as librarians and 
was predefined in a peer-reviewed protocol. However, the 
possibility remains that not all potentially relevant studies 
were identified, which could be classified as an additional 
source of bias. Given the limited number of seven metastatic 
events, we refrained from running multivariable regression 
analyses and larger datasets are needed to develop prediction 
models involving several risk factors. The current analysis 
provides a unique overview of the published experience with 
juvenile and adult tGrCT. It may help physicians differenti-
ate between tGrCT with a lower or higher risk for metastatic 
disease and select the most appropriate treatment modality 
for tGrCT patients.
Due to the absence of prospective trials, we recently 
opened the OrphAn Testis Histologies (OATH) to provide 
more conclusive recommendations regarding clinical course, 
management and follow-up of these rare entities. We encour-
age collaborators to contribute data of patients with rare tes-
tis cancer histologies (http://bit.ly/OATH-regis try).
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